#ESMO26 Our trial of the #KRAS vaccine 馃拤presented today alongside concurrent publication in @NatureMedicine!
The RAS-revolution continues. Excited about future development, role of ctDNA, and combinatorial strategies.
G12D
R
V
S
A
C
&
G13D
@OncoAlert
https://www.nature.com/articles/s41591-026-04734-7
2578 views 路 48 likes 路 7 reposts 路 0 replies
Calderasib monotherapy in various KRAS G12C鈥搈utated advanced solid tumors: Results from the phase 1 KANDLELIT-001 study
https://esmocongress.esmo.orgKrascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.orgFirst-line (1L) olomorasib + pembrolizumab in KRAS G12C-mutant NSCLC: Updated results from LOXO-RAS-20001 and SUNRAY-01
https://esmocongress.esmo.orgSource: Pashtoon Kasi MD, MS 路 x.com